Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 5/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 2/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861135 | 0.89 | ERN1 (0.65) | ERN1ALDH1A1CA12CA9CA1 | |
| SCHEMBL31013334 | 0.89 | ERN1 (0.65) | ERN1ALDH1A1CA12CA9CA1 | |
| SCHEMBL29929690 | 0.88 | ERN1 (0.63) | ERN1ALDH1A1CA12CA9CA1 | |
| SCHEMBL27715902 | 0.87 | CA12 (0.71) | ERN1CA12CA9CA1CA2 | |
| SCHEMBL1537555 | 0.85 | ALDH1A1 (0.68) | ERN1ALDH1A1CA12CA9CA1 | |
| SCHEMBL68931 | 0.85 | CA12 (0.69) | ERN1CA12CA9CA1CA2 | |
| SCHEMBL67941 | 0.85 | CA12 (0.68) | ERN1CA12CA9CA1CA2 | |
| SCHEMBL881425 | 0.84 | TRIM24 (0.67) | ERN1ALDH1A1CA12CA9CA1 | |
| SCHEMBL6472650 | 0.84 | TP53 (0.61) | ERN1ALDH1A1 | |
| SCHEMBL2389679 | 0.83 | ALDH1A1 (0.89) | ERN1ALDH1A1CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| CN-108349875-B | Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient | 东国大学校产学协力团 | 2021-08-27 | — | — | CN | disclosed |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-08-02 | — | — | US | disclosed |
| EP-3327001-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
| US-9522873-B2 | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-12-20 | — | — | US | disclosed |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | IMMUSOL INCORPORATED (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | IMMUSOL INCORPORATED (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | IMMUSOL INCORPORATED (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1841428-A1 | NOVEL QUINOLINIUM SALTS AND DERIVATIVES | Immusol Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | disclosed |
| US-6649633-B2 | For treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-11-18 | — | — | US | disclosed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| CN-1333766-A | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors | AVENTIS PHARM PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | ERN1 879/4885ALDH1A1 607/4885CA12 4115/4885 |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | NQO2, MCL1, KRAS | ERN1 2891/4885ALDH1A1 3206/4885CA12 3588/4885 |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | CD47, MSR1, CD14 | ERN1 4596/4885ALDH1A1 2184/4885CA12 3572/4885 |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | ERN1 3931/4885ALDH1A1 3365/4885CA12 4039/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | ERN1 3978/4885ALDH1A1 2804/4885CA12 1304/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | ERN1 877/4885ALDH1A1 584/4885CA12 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.